Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Enhancing the quality and trustworthiness of large language model-generated summaries of clinical oncology literature.

JAMIA open·2026
Same author

Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer.

Cancer·2026
Same author

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

JCO precision oncology·2026
Same author

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Research square·2026
Same author

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Future oncology (London, England)·2026

Related Experiment Video

Updated: May 9, 2026

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples
07:32

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples

Published on: June 15, 2012

Development of a method to isolate circulating tumor cells using mesenchymal-based capture.

Rhonda L Bitting1, Rengasamy Boominathan, Chandra Rao

  • 1Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC, United States; Department of Medicine, Duke University, Durham, NC, United States; Center for RNA Biology, Duke University, Durham, NC, United States.

Methods (San Diego, Calif.)
|July 13, 2013
PubMed
Summary

Researchers developed a new method to detect circulating tumor cells (CTCs) by identifying mesenchymal cells, which are crucial in metastasis. This novel assay shows promise for improving cancer detection, especially in prostate cancer patients.

Keywords:
Circulating tumor cellsEpithelial plasticityEpithelial–mesenchymal transitionOB-cadherinOsteomimicryProstate cancer

More Related Videos

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Capture and Release of Viable Circulating Tumor Cells from Blood
08:10

Capture and Release of Viable Circulating Tumor Cells from Blood

Published on: October 28, 2016

Related Experiment Videos

Last Updated: May 9, 2026

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples
07:32

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples

Published on: June 15, 2012

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Capture and Release of Viable Circulating Tumor Cells from Blood
08:10

Capture and Release of Viable Circulating Tumor Cells from Blood

Published on: October 28, 2016

Area of Science:

  • Oncology
  • Cell Biology
  • Cancer Metastasis

Background:

  • Epithelial plasticity allows tumor cells to transition between epithelial and mesenchymal phenotypes.
  • Metastasis involves circulating tumor cells (CTCs) potentially losing their epithelial traits.
  • Current CTC technologies may not fully capture these mesenchymal-transitioned cells.

Purpose of the Study:

  • To develop a novel CTC capture method targeting the mesenchymal phenotype.
  • To investigate OB-cadherin expression as a marker for mesenchymal CTCs.
  • To assess the utility of this method in detecting metastatic prostate cancer.

Main Methods:

  • Development of a novel CTC capture assay based on epithelial plasticity.
  • Isolation of cells utilizing OB-cadherin cell surface expression.
  • Application of the assay to detect OB-cadherin cellular events in patient samples.

Main Results:

  • OB-cadherin cellular events were detected in men with metastatic prostate cancer.
  • These events were found to be less common in healthy volunteers.
  • The developed method shows potential for complementary use with existing epithelial-based CTC assays.

Conclusions:

  • A novel mesenchymal-based CTC capture method has been developed.
  • This assay effectively detects OB-cadherin expression in metastatic prostate cancer patients.
  • The method may enhance CTC detection, particularly for patients with bone metastases.